臨床検査医学

Medicine & Life Sciences

1. SARS Virus 100%
2. Japan 88%
3. Mycobacterium avium Complex 80%
4. Blood Platelets 78%
5. Coronavirus 74%
6. Lung 59%
7. Pulmonary Hypertension 58%
8. Platelet Glycoprotein GPIb-IX Complex 56%
9. Lung Diseases 54%
10. Infections 50%
11. von Willebrand Factor 47%
12. Transcatheter Aortic Valve Replacement 46%
13. Balloon Angioplasty 44%
14. Vaccination 44%
15. Severe Acute Respiratory Syndrome 43%
16. Antibodies 35%
17. Genes 34%
18. Serum 33%
19. Genotype 32%
20. Therapeutics 31%
21. Platelet Membrane Glycoproteins 30%
22. Aspirin 30%
23. Three-Dimensional Echocardiography 29%
24. Acute Promyelocytic Leukemia 28%
25. Echocardiography 28%
26. Platelet Aggregation 28%
27. Megakaryocytes 26%
28. Mutation 26%
29. Hematopoietic Stem Cell Transplantation 26%
30. Thrombotic Thrombocytopenic Purpura 26%
31. University Hospitals 24%
32. Aortic Valve Insufficiency 24%
33. Health Personnel 24%
34. Population 24%
35. Cross-Sectional Studies 24%
36. Tokyo 24%
37. Migraine Disorders 24%
38. riociguat 24%
39. Cellular Immunity 24%
40. Right Ventricular Function 24%
41. Neoplasms 24%
42. Standing Position 23%
43. Hemodynamics 23%
44. Polymerase Chain Reaction 22%
45. Transesophageal Echocardiography 22%
46. Vaccines 22%
47. Observational Studies 22%
48. Anticoagulants 22%
49. In Vitro Techniques 22%
50. Chronic Obstructive Pulmonary Disease 21%
51. Cerebrovascular Disorders 21%
52. Thrombosis 21%
53. human MIRN346 microRNA 21%
54. Incidence 20%
55. Homologous Transplantation 20%
56. Bone Marrow Transplantation 20%
57. Supine Position 20%
58. Liposomes 20%
59. Obstructive Sleep Apnea 20%
60. Odds Ratio 20%
61. Hematology 20%
62. Stroke Volume 19%
63. Elderly 19%
64. Confidence Intervals 18%
65. Tretinoin 18%
66. Coronary Artery Disease 18%
67. Integrins 18%
68. Antithrombins 18%
69. Tomography 18%
70. fremanezumab 18%
71. Cell Line 17%
72. Cohort Studies 17%
73. Idiopathic Thrombocytopenic Purpura 17%
74. Myeloid Cells 17%
75. Pneumocystis Pneumonia 17%
76. Mycobacterium abscessus 17%
77. Epitopes 17%
78. Pulmonary Arterial Hypertension 16%
79. Mitral Valve Insufficiency 16%
80. Genetic Polymorphisms 16%
81. Acquired Thrombotic thrombocytopenic purpura 16%
82. Primary Prevention 16%
83. Mycobacterium 16%
84. Bone Marrow 16%
85. Neutralizing Antibodies 16%
86. galcanezumab 16%
87. Alleles 15%
88. Humoral Immunity 15%
89. Monoclonal Antibodies 15%
90. Autoantibodies 15%
91. Acute Lung Injury 15%
92. polyglucosan 15%
93. Thrombopoietin 15%
94. Liver 15%
95. Fibrinogen 14%
96. Immunoglobulin G 14%
97. Pneumonia 14%
98. Stem Cells 14%
99. Single Nucleotide Polymorphism 14%
100. Bacteremia 14%